Page 53 - fbkCardioDiabetes_2017

Glucose is Not Always Sweet Diabetic Kidney Disease: 29
Can we Make it “SWEET” Again?

The understanding of the putative renoprotective role
of SGLT2 and GLP-1 will help towards the understand-
ing their cardiovascular and (putative) reno-protective
effect and possibly offer new target for treatment in
the future.

Highlights
• Diabetic kidney disease is the major cause of end
stage renal failure.
• Diabetic nephropathy is an irreversible progres-
sive disease though some evidence suggests its
reversibility.
• As diabetic renal diseases progress hypoglycae-
mic and blood pressure treatment needs to be
personalized to preserve patient safety.
• Preliminary studies strongly suggest a renoprotec-
tive role of SGLT2 antagonist and GLP-1 analogues.
• The cardiovascular protective role of SGLT2 antag-
onist and GLP-1 analogues is likely to be mediated
by haemodynamic effects affecting the cardiovas-
cular renal system.

References:
3. Gnudi L, Gentile, G., Ruggenenti, P. The patient with diabetes mellitus.
In: Turner N, Lamiere, N., Goldsmith, D.J.,Wineearls, C.G., Himmelfarb,
J., Remuzzi, G., editor. Oxford Textbook of Clinical Nephrology. 2. Oxford,
UK: Oxford University Press; 2016. p. 1199-247.
4. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer, M. Reversal of
lesions of diabetic nephropathy after pancreas transplantation [see com-
ments]. New England Journal of Medicine. 1998;339(2):69-75.
5. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovas-
cular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11-
26.
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med. 2015;373(22):2117-28.
7. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mat-
theus M, et al. Empagliflozin and Progression of Kidney Disease in Type
2 Diabetes. N Engl J Med. 2016.
8. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck
MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med. 2016;375(4):311-22.
9. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor ago-
nists. Cardiovasc Ther. 2012;30(3):e146-55.

Cardio Diabetes Medicine